For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

3rd May 21

Pharmaxis and Charlie Teo Foundation Identify Promising New Drug to Tackle Brain Cancer

Unique mechanism of drug action inhibits enzymes critical to tumour growth and survival

An Australian drug discovery will be the focus of a new study to tackle an aggressive and deadly form of brain cancer with a funding grant from the Charlie Teo Foundation. The drug, developed by Sydney-based research company Pharmaxis (ASX: PXS), will enter pre-clinical efficacy testing for glioblastoma (GBM), the most common form of brain cancer with an average survival of only 15 months from diagnosis.

Read full media release - pdf
14th Apr 21

Pharmaxis Sells Bronchitol Russian Distribution Rights for A$2m with Annual A$1m Cost Savings


  • Pharmaxis sells distribution rights for Bronchitol in Russia effective May 1st 2021
  • Pharmaxis to receive a €1.25 million (~A$2m) distributor appointment fee
  • Annual cost savings of approximately A$1m realised from transfer of commercial and product responsibilities
Read full media release - pdf
14th Apr 21

Pharmaxis Announces A$4.4m Placement


  • A$4.4m being raised in a placement to institutional investors
  • A$20m pro-forma cash balance post raising  
  • Strengthened balance sheet to support ongoing clinical studies in myelofibrosis and skin scarring  
  • Issue price of A$0.08 represents a 1.3% premium to last closing price as at 12 April 2021
  • New shareholder Karst Peak Capital Limited invests A$3.2m for a 8.9% holding in the Company
  • Existing shareholder BVF Partners LP invests A$0.8m to maintain its holding at 19.5%
Read full media release - pdf